"One needs to ask themselves why after all this time since Lancet release, we've just go down bigtime, why the so called 'smart money' isn't rushing in to buy and why the share price isn't zillions of dollars higher?
The answer imo, is individuals have gotten totally carried away by the early sketchy developing Ocata science and the so called 'smart money' knows the company has miles and miles of clinicals and millions and millions of funding, and then the FDA to go."
I do not agree with you about the "smart money." I think it is more of the "institutional money" that, in my view, wants to get in but really can't because of internal restrictions on investing in a company in this stage of its development (financial and scientific). It is the kind of stock the individual fund manager might buy in an individual account which is not going to move the needle, but when the time comes for the brokerage house to get the green light, he is off to the races to sell the story to all of his clients. So, yes, of course there is still a long way to go- that is the nature of the beast. But I do not believe it is a matter of smart money. rather, it is a matter of investing in something you believe will be a massive success down the road and therefore worth the current investment risk. If it plays out well, we will know who the "smart money" people were.
News 
Market Data 
Discover 
AI
